10 March 2020 - PHARMAC is pleased to announce the approval of a decision to fund a new topical psoriasis medicine, betamethasone dipropionate with calcipotriol foam spray (Enstilar) from 1 April 2020, through a listing agreement with Leo Pharma.

The decision also includes changes to pack sizes and prices for the following currently funded medicines supplied by Leo Pharma:

• Calcipotriol ointment 50 mcg per g (Daivonex) – used topically for psoriasis – 120 g pack would replace 100 g pack from 1 July 2020
• Sodium fusidate [fusidic acid] 250 mg tablets (Fucidin) – oral antibiotic used for the treatment of staphylococcal infections – 36 tablet pack would replace the 12 tablet pack from 1 December 2020
• Hydrocortisone butyrate lipocream 0.1% (Locoid Lipocream) – used for skin conditions such as eczema, dermatitis and psoriasis – 100 g pack would remain listed and 30 g pack would be delisted.

Read PHARMAC press release